140 related articles for article (PubMed ID: 28176019)
1. Long-term treatment with EGFR inhibitor erlotinib attenuates renal inflammatory cytokines but not nephropathy in Alport syndrome mouse model.
Omachi K; Miyakita R; Fukuda R; Kai Y; Suico MA; Yokota T; Kamura M; Shuto T; Kai H
Clin Exp Nephrol; 2017 Dec; 21(6):952-960. PubMed ID: 28176019
[TBL] [Abstract][Full Text] [Related]
2. STAT3 inhibition attenuates the progressive phenotypes of Alport syndrome mouse model.
Yokota T; Omachi K; Suico MA; Kamura M; Kojima H; Fukuda R; Motomura K; Teramoto K; Kaseda S; Kuwazuru J; Takeo T; Nakagata N; Shuto T; Kai H
Nephrol Dial Transplant; 2018 Feb; 33(2):214-223. PubMed ID: 28992339
[TBL] [Abstract][Full Text] [Related]
3. The role of discoidin domain receptor 2 in the renal dysfunction of alport syndrome mouse model.
Sannomiya Y; Kaseda S; Kamura M; Yamamoto H; Yamada H; Inamoto M; Kuwazuru J; Niino S; Shuto T; Suico MA; Kai H
Ren Fail; 2021 Dec; 43(1):510-519. PubMed ID: 33706638
[TBL] [Abstract][Full Text] [Related]
4. Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimental Alport syndrome.
Bae EH; Fang F; Williams VR; Konvalinka A; Zhou X; Patel VB; Song X; John R; Oudit GY; Pei Y; Scholey JW
Kidney Int; 2017 Jun; 91(6):1347-1361. PubMed ID: 28249676
[TBL] [Abstract][Full Text] [Related]
5. Bromide supplementation exacerbated the renal dysfunction, injury and fibrosis in a mouse model of Alport syndrome.
Yokota T; Omachi K; Suico MA; Kojima H; Kamura M; Teramoto K; Kaseda S; Kuwazuru J; Shuto T; Kai H
PLoS One; 2017; 12(9):e0183959. PubMed ID: 28873450
[TBL] [Abstract][Full Text] [Related]
6. Collagen receptors integrin alpha2beta1 and discoidin domain receptor 1 regulate maturation of the glomerular basement membrane and loss of integrin alpha2beta1 delays kidney fibrosis in COL4A3 knockout mice.
Rubel D; Frese J; Martin M; Leibnitz A; Girgert R; Miosge N; Eckes B; Müller GA; Gross O
Matrix Biol; 2014 Feb; 34():13-21. PubMed ID: 24480069
[TBL] [Abstract][Full Text] [Related]
7. Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome.
Koepke ML; Weber M; Schulze-Lohoff E; Beirowski B; Segerer S; Gross O
Nephrol Dial Transplant; 2007 Apr; 22(4):1062-9. PubMed ID: 17287218
[TBL] [Abstract][Full Text] [Related]
8. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.
Gross O; Beirowski B; Koepke ML; Kuck J; Reiner M; Addicks K; Smyth N; Schulze-Lohoff E; Weber M
Kidney Int; 2003 Feb; 63(2):438-46. PubMed ID: 12631109
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor signaling mediates aldosterone-induced profibrotic responses in kidney.
Sheng L; Yang M; Ding W; Zhang M; Niu J; Qiao Z; Gu Y
Exp Cell Res; 2016 Aug; 346(1):99-110. PubMed ID: 27317889
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Epidermal Growth Factor Receptor Activation Is Associated With Improved Diabetic Nephropathy and Insulin Resistance in Type 2 Diabetes.
Li Z; Li Y; Overstreet JM; Chung S; Niu A; Fan X; Wang S; Wang Y; Zhang MZ; Harris RC
Diabetes; 2018 Sep; 67(9):1847-1857. PubMed ID: 29959129
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib attenuates the progression of chronic kidney disease in rats with remnant kidney.
Yamamoto Y; Iyoda M; Tachibana S; Matsumoto K; Wada Y; Suzuki T; Iseri K; Saito T; Fukuda-Hihara K; Shibata T
Nephrol Dial Transplant; 2018 Apr; 33(4):598-606. PubMed ID: 28992288
[TBL] [Abstract][Full Text] [Related]
12. Mild electrical stimulation and heat shock ameliorates progressive proteinuria and renal inflammation in mouse model of Alport syndrome.
Koga T; Kai Y; Fukuda R; Morino-Koga S; Suico MA; Koyama K; Sato T; Shuto T; Kai H
PLoS One; 2012; 7(8):e43852. PubMed ID: 22937108
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine a slows the progressive renal disease of alport syndrome (X-linked hereditary nephritis): results from a canine model.
Chen D; Jefferson B; Harvey SJ; Zheng K; Gartley CJ; Jacobs RM; Thorner PS
J Am Soc Nephrol; 2003 Mar; 14(3):690-8. PubMed ID: 12595505
[TBL] [Abstract][Full Text] [Related]
14. A Neutralizing IL-11 Antibody Improves Renal Function and Increases Lifespan in a Mouse Model of Alport Syndrome.
Widjaja AA; Shekeran SG; Adami E; Ting JGW; Tan J; Viswanathan S; Lim SY; Tan PH; Hübner N; Coffman T; Cook SA
J Am Soc Nephrol; 2022 Apr; 33(4):718-730. PubMed ID: 35140116
[TBL] [Abstract][Full Text] [Related]
15. [Alport syndrome: Hereditary nephropathy associated with mutations in genes coding for type IV collagen chains].
Heidet L; Gubler MC
Nephrol Ther; 2016 Dec; 12(7):544-551. PubMed ID: 27816395
[TBL] [Abstract][Full Text] [Related]
16. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
17. Albumin contributes to kidney disease progression in Alport syndrome.
Jarad G; Knutsen RH; Mecham RP; Miner JH
Am J Physiol Renal Physiol; 2016 Jul; 311(1):F120-30. PubMed ID: 27147675
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor inhibition with erlotinib ameliorates anti-Thy 1.1-induced experimental glomerulonephritis.
Rintala JM; Savikko J; Rintala SE; Palin N; Koskinen PK
J Nephrol; 2016 Jun; 29(3):359-365. PubMed ID: 26423803
[TBL] [Abstract][Full Text] [Related]
19. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
Li H; Wang S; Takayama K; Harada T; Okamoto I; Iwama E; Fujii A; Ota K; Hidaka N; Kawano Y; Nakanishi Y
Lung Cancer; 2015 Apr; 88(1):1-8. PubMed ID: 25670150
[TBL] [Abstract][Full Text] [Related]
20. Laminin compensation in collagen alpha3(IV) knockout (Alport) glomeruli contributes to permeability defects.
Abrahamson DR; Isom K; Roach E; Stroganova L; Zelenchuk A; Miner JH; St John PL
J Am Soc Nephrol; 2007 Sep; 18(9):2465-72. PubMed ID: 17699809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
